MaxCyte Inc (NASDAQ: MXCT) on Tuesday, plunged -3.98% from the previous trading day, before settling in for the closing price of $3.77. Within the past 52 weeks, MXCT’s price has moved between $3.16 and $5.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 18.61%. The company achieved an average annual earnings per share of -7.33%. With a float of $97.35 million, this company’s outstanding shares have now reached $105.30 million.
Let’s determine the extent of company efficiency that accounts for 143 employees. In terms of profitability, gross margin is 79.04%, operating margin of -101.56%, and the pretax margin is -78.36%.
MaxCyte Inc (MXCT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of MaxCyte Inc is 7.71%, while institutional ownership is 71.43%. The most recent insider transaction that took place on Jan 27 ’25, was worth 13,935. In this transaction Director of this company sold 3,000 shares at a rate of $4.64, taking the stock ownership to the 141,950 shares. Before that another transaction happened on Jan 13 ’25, when Company’s GENERAL COUNSEL sold 4,466 for $4.54, making the entire transaction worth $20,272. This insider now owns 41,447 shares in total.
MaxCyte Inc (MXCT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.10% during the next five years compared to -16.20% drop over the previous five years of trading.
MaxCyte Inc (NASDAQ: MXCT) Trading Performance Indicators
MaxCyte Inc (MXCT) is currently performing well based on its current performance indicators. A quick ratio of 9.22 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.34, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.38 in one year’s time.
Technical Analysis of MaxCyte Inc (MXCT)
Looking closely at MaxCyte Inc (NASDAQ: MXCT), its last 5-days average volume was 0.35 million, which is a drop from its year-to-date volume of 0.54 million. As of the previous 9 days, the stock’s Stochastic %D was 5.72%. Additionally, its Average True Range was 0.24.
During the past 100 days, MaxCyte Inc’s (MXCT) raw stochastic average was set at 22.36%, which indicates a significant increase from 1.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.57% in the past 14 days, which was lower than the 57.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.36, while its 200-day Moving Average is $4.18. However, in the short run, MaxCyte Inc’s stock first resistance to watch stands at $3.86. Second resistance stands at $4.10. The third major resistance level sits at $4.23. If the price goes on to break the first support level at $3.49, it is likely to go to the next support level at $3.36. Now, if the price goes above the second support level, the third support stands at $3.12.
MaxCyte Inc (NASDAQ: MXCT) Key Stats
Market capitalization of the company is 381.85 million based on 105,846K outstanding shares. Right now, sales total 41,290 K and income totals -37,920 K. The company made 8,160 K in profit during its latest quarter, and -11,560 K in sales during its previous quarter.
